Xinzhao Wang

  • Citations Per Year
Learn More
Triple-negative breast cancer (TNBC) accounts for 20% of all molecular subtypes of breast cancer. Neither endocrine nor anti-HER2 molecular targeting treatment yield promising results. At present, epidermal growth factor receptor (EGFR) inhibitor, as a single agent, is unable to obtain encouraging results in the treatment of TNBC, even though most of these(More)
Epidermal growth factor receptor (EGFR) is over-expressed in about 50% of Triple negative breast cancers (TNBCs), but EGFR inhibitors have not been effective in treating TNBC patients. Increasing evidence supports that autophagy was related to drug resistance at present. However, the role and the mechanism of autophagy to the treatment of TNBC remain(More)
Breast cancer subtype was defined by ER, PR, HER2 and Ki67 status since the definition of intrinsic subtypes for breast cancer was renovated in 2013 St. Gallen Consensus Conference. The level of ER, PR, HER2 and Ki67 are the main predictive and prognostic biomarkers in various breast carcinoma subtypes. We retrospectively analyzed clinic pathological(More)
To investigate the effects of the centrosomal protein, ninein-like protein (Nlp), on the proliferation, invasion and metastasis of MCF-7 breast cancer cells, the present study established green fluorescent protein (GFP)-containing MCF7 plasmids with steady and overexpression of Nlp (MCG7-GFP-N1p) and blank plasmids (MCF7-GFP) using lentiviral transfection(More)
AIM To evaluate the efficacy and toxicity of vinorelbine and gemcitabine (NG) versus vinorelbine and cisplatin (NP) in anthracycline- and taxane-pretreated patients with HER2-negative advanced breast cancer. PATIENTS AND METHODS Patients were randomly assigned on a 1:1 schedule to receive no more than six cycles of NG or NP. Dosing for the NG group was 25(More)
Sentinel lymph node biopsy substituting axillary lymph node dissection has become a routine surgery in many countries but not in China because of the false negative rate. False negative (FN) of sentinel lymph node (SLN) can lead an incorrect assessment of pathological staging. In this study, we retrospectively analyzed the clinic pathological data of 645(More)
OBJECTIVE To observe the impact of concurrent administration of recombinant human p53 adenovirus (Ad-p53) with EGFR inhibitor gefitinib on breast cancer MDA-MB-468 cells. METHODS MDA-MB-468 cells were treated with Ad-p53 and/or gefitinib. The effect of Ad-p53 and gefitinib on the growth of MDA-MB-468 cells was evaluated by MTT assay. Cell apoptosis was(More)
  • 1